The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.65BTWD
161.03M · vs all stocks (USD)
Updated Nov 15, 2026
Revenue (TTM)
815.87MTWD
25.26M · vs all stocks (USD)
Updated Nov 15, 2026
Profit Margin
-46.81%
vs Biotechnology peers
Updated Nov 15, 2026
Beta
0.4760x
vs all stocks
Updated Nov 15, 2026
52-Week Change
-30.71%
vs all stocks
Updated Nov 15, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Nov 15, 2026
Market Capitalization
4.65BTWD
161.03M · vs all stocks (USD)
Updated Nov 15, 2026
Enterprise Value
5.51BTWD
188.90M · vs all stocks (USD)
Updated Nov 15, 2026
Price to Sales (TTM)
5.70x
vs Biotechnology peers
Updated Nov 15, 2026
Price to Book (MRQ)
3.30x
vs Biotechnology peers
Updated Nov 15, 2026
Enterprise to Revenue
6.75x
vs Biotechnology peers
Updated Nov 15, 2026
Enterprise to EBITDA
-56.98x
vs Biotechnology peers
Updated Nov 15, 2026
Gross Margin
-9.04%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives -16.88%.Updated Nov 15, 2026
Profit Margin
-46.81%
vs Biotechnology peers
Updated Nov 15, 2026
Operating Margin
-43.68%
vs Biotechnology peers
Updated Nov 15, 2026
Return on Assets (TTM)
-6.86%
vs Biotechnology peers
Updated Nov 15, 2026
Return on Equity (TTM)
-24.06%
vs Biotechnology peers
Updated Nov 15, 2026
Revenue (TTM)
815.87MTWD
25.26M · vs all stocks (USD)
Updated Nov 15, 2026
Revenue per Share (TTM)
3.94TWDUpdated Nov 15, 2026
Quarterly Revenue Growth
0.30%
vs Biotechnology peers
Updated Nov 15, 2026
Gross Profit (TTM)
-137.68MTWD
-5.02M · vs all stocks (USD)
Updated Nov 15, 2026
EBITDA (TTM)
-96.67MTWD
-4.35M · vs all stocks (USD)
Updated Nov 15, 2026
Net Income (TTM)
-381.91MTWD
-13.53M · vs all stocks (USD)
Updated Nov 15, 2026
Quarterly Earnings Growth (YoY)
0.26%
vs Biotechnology peers
Updated Nov 15, 2026
Operating Cash Flow (TTM)
122.68MTWD
-2.09M · vs all stocks (USD)
Updated Nov 15, 2026
Levered Free Cash Flow (TTM)
94.77MTWD
-625.07K · vs all stocks (USD)
Updated Nov 15, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Nov 15, 2026
Trailing Annual Dividend Rate
0.00TWDUpdated Nov 15, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Nov 15, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Nov 15, 2026
Revenue
740.24MTWDFY2025 · Dec 31, 2025
Cost of Goods Sold
921.65MTWDFY2025 · Dec 31, 2025
Gross Profit
-181.41MTWDFY2025 · Dec 31, 2025
Operating Income
-405.39MTWD
-12.56M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-454.11MTWDFY2025 · Dec 31, 2025
Income Tax Expense
-5.48MTWDFY2025 · Dec 31, 2025
Net Income
-448.63MTWDFY2025 · Dec 31, 2025
EBIT
-420.44MTWDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-137.66MTWDFY2025 · Dec 31, 2025
Research & Development
75.91MTWDFY2025 · Dec 31, 2025
Selling, General & Administrative
148.07MTWDFY2025 · Dec 31, 2025
Non-operating Interest Income
3.12MTWDFY2025 · Dec 31, 2025
Non-operating Interest Expense
33.67MTWDFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025
Operating Cash Flow
-375.44MTWDFY2025 · Dec 31, 2025
Free Cash Flow
-463.50MTWDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
224.54MTWDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-454.11MTWDFY2025 · Dec 31, 2025
Stock-based Compensation
20.13MTWDFY2025 · Dec 31, 2025
Other Non-cash Items
30.55MTWDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-12.37MTWDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
40.36MTWDFY2025 · Dec 31, 2025
Capital Expenditures
-88.06MTWDFY2025 · Dec 31, 2025
Net Intangibles (CF)
-10.54MTWDFY2025 · Dec 31, 2025
Net Acquisitions
0.00TWDFY2025 · Dec 31, 2025
Purchase of Investments
-24.05MTWDFY2025 · Dec 31, 2025
Sale of Investments
7.30MTWDFY2025 · Dec 31, 2025
Other Investing Activity
-205.00KTWDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-105.02MTWDFY2025 · Dec 31, 2025
Long-term Debt Issuance
0.00TWDFY2025 · Dec 31, 2025
Long-term Debt Payments
-149.22MTWDFY2025 · Dec 31, 2025
Net Short-term Debt Issuance
280.00MTWDFY2025 · Dec 31, 2025
Common Stock Repurchase
0.00TWDFY2025 · Dec 31, 2025
Net Financing Cash Flow
136.22MTWDFY2025 · Dec 31, 2025
Shares Outstanding
207.04MSharesUpdated Nov 15, 2026
Float Shares
112.98MSharesUpdated Nov 15, 2026
% Held by Insiders
47.55%
vs all stocks
Updated Nov 15, 2026
% Held by Institutions
0.04%
vs all stocks
Updated Nov 15, 2026
Total Cash (MRQ)
263.74MTWD
6.70M · vs all stocks (USD)
Updated Nov 15, 2026
Total Cash per Share (MRQ)
1.27TWDUpdated Nov 15, 2026
Total Debt (MRQ)
1.12BTWD
36.67M · vs all stocks (USD)
Updated Nov 15, 2026
Total Debt to Equity (MRQ)
0.7984x
vs Biotechnology peers
Updated Nov 15, 2026
Current Ratio (MRQ)
0.6080x
vs Biotechnology peers
Updated Nov 15, 2026
Book Value per Share (MRQ)
6.80TWDUpdated Nov 15, 2026
Total Assets
3.26BTWD
101.06M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
776.02MTWDFY2025 · Dec 31, 2025
Total Liabilities
1.66BTWDFY2025 · Dec 31, 2025
Total Non-current Assets
2.49BTWDFY2025 · Dec 31, 2025
Total Non-current Liabilities
556.13MTWDFY2025 · Dec 31, 2025
Total Current Liabilities
1.11BTWDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
224.54MTWDFY2025 · Dec 31, 2025
Other Short-term Investments
1.20MTWDFY2025 · Dec 31, 2025
Accounts Receivable
106.27MTWDFY2025 · Dec 31, 2025
Inventory
132.89MTWDFY2025 · Dec 31, 2025
Accounts Payable
77.47MTWDFY2025 · Dec 31, 2025
Short-term Debt
515.76MTWDFY2025 · Dec 31, 2025
Other Current Liabilities
1.74MTWDFY2025 · Dec 31, 2025
Long-term Debt
556.13MTWDFY2025 · Dec 31, 2025
Common Stock (Book)
2.07BTWDFY2025 · Dec 31, 2025
Retained Earnings
-540.63MTWDFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.60BTWD
49.55M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
19.95TWDUpdated Nov 15, 2026
52-Week High
37.00TWDUpdated Nov 15, 2026
52-Week Change
-30.71%
vs all stocks
Updated Nov 15, 2026
Beta
0.4760x
vs all stocks
Updated Nov 15, 2026
50-Day MA
22.74TWDUpdated Nov 15, 2026
200-Day MA
26.90TWDUpdated Nov 15, 2026
Avg 10-Day Volume
214.82KSharesUpdated Nov 15, 2026
Avg 30-Day Volume
138.23KSharesUpdated Nov 15, 2026
Diluted EPS (TTM)
-1.86TWDUpdated Nov 15, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 1.8%, lower than 95% of its Biotechnology peers (median 65.4%)Significant